Cargando…
BCR-ABL突变检测指导下的达沙替尼治疗伊马替尼耐药的慢性髓性白血病疗效分析
OBJECTIVE: To evaluate the efficiency of dasatinib as the second- or third-line tyrosine kinase inhibitor (TKI) in imatinib-resistant patients with chronic myeloid leukemia (CML) based on BCR-ABL mutation detection. METHODS: 122 CML patients received dasatinib treatment, including 83 with imatinib-r...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342298/ https://www.ncbi.nlm.nih.gov/pubmed/26876246 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.01.002 |